Replimune Group (NASDAQ:REPL) Insider Sells $47,392.80 in Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 5,208 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $47,392.80. Following the transaction, the insider owned 123,088 shares in the company, valued at approximately $1,120,100.80. This trade represents a 4.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Replimune Group Stock Performance

NASDAQ:REPL traded up $0.25 during mid-day trading on Wednesday, hitting $8.99. 1,895,576 shares of the stock were exchanged, compared to its average volume of 4,388,618. The firm’s 50-day simple moving average is $6.56 and its 200 day simple moving average is $7.39. The stock has a market capitalization of $705.18 million, a price-to-earnings ratio of -2.60 and a beta of 0.80. Replimune Group, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). As a group, equities analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Barclays lowered shares of Replimune Group from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Piper Sandler upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research report on Monday, October 20th. Jefferies Financial Group lowered their target price on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target for the company in a research report on Monday, October 20th. Finally, Cantor Fitzgerald upgraded Replimune Group from a “neutral” rating to an “overweight” rating in a research note on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Replimune Group has a consensus rating of “Moderate Buy” and an average price target of $9.75.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently made changes to their positions in REPL. Readystate Asset Management LP raised its holdings in shares of Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after buying an additional 2,433,292 shares in the last quarter. Braidwell LP boosted its stake in Replimune Group by 550.3% in the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after buying an additional 2,327,205 shares in the last quarter. Balyasny Asset Management L.P. grew its position in Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after acquiring an additional 2,195,448 shares during the last quarter. Erste Asset Management GmbH raised its stake in Replimune Group by 13,597.5% during the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after acquiring an additional 1,618,100 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Replimune Group in the first quarter worth about $6,546,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.